Cargando…

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong

After more than 40 years of clinical use, levodopa (LD) remains the gold standard of symptomatic efficacy in the drug treatment of Parkinson’s disease (PD). Compared with other available dopaminergic therapies, dopamine replacement with LD is associated with the greatest improvement in motor functio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poewe, Werner, Antonini, Angelo, Zijlmans, Jan CM, Burkhard, Pierre R, Vingerhoets, François
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938030/ https://www.ncbi.nlm.nih.gov/pubmed/20852670

Ejemplares similares

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Levodopa–carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2019)

Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
por: Poewe, Werner, et al.
Publicado: (2019)

Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2020)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

Electroconvulsive therapy: 80 years old and still going strong
por: Gazdag, Gábor, et al.
Publicado: (2019)

25 years... and still going strong
Publicado: (1984)

Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Beyond the Dopaminergic System: Lessons Learned from levodopa Resistant Symptoms in Parkinson's Disease
por: Antonini, Angelo, et al.
Publicado: (2023)

At 88, Herman Wouk is still going strong
por: Herman, J
Publicado: (2004)

GFORCE-PD still going strong in 2016
por: Parmar, Malin, et al.
Publicado: (2017)

Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel
por: Ray Chaudhuri, K., et al.
Publicado: (2018)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: Rocha, José-Francisco, et al.
Publicado: (2021)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study
por: Olanow, C. Warren, et al.
Publicado: (2021)

Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
por: Antonini, Angelo, et al.
Publicado: (2016)

The noncoding RNA revolution—three decades and still going strong!
por: Calin, George A.
Publicado: (2019)

The Gene Ontology Resource: 20 years and still GOing strong
Publicado: (2019)

Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson’s Disease
por: Fabbri, Margherita, et al.
Publicado: (2017)

mSphere of Influence: the Power of Yeast Genetics Still Going Strong!
por: Santiago-Tirado, Felipe H.
Publicado: (2019)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

Microtubule dynamics: 50 years after the discovery of tubulin and still going strong
por: Pigino, Gaia, et al.
Publicado: (2017)

Still going strong? The role of traditional media in the 2021 Dutch parliamentary elections
por: Vermeer, Susan, et al.
Publicado: (2022)

Continuous levodopa for advanced Parkinson’s disease
por: Lundqvist, Christofer
Publicado: (2007)

Levodopa-Responsive Benign Tremulous Parkinsonism
por: Kano, Osamu, et al.
Publicado: (2013)

Mortality in Levodopa-Treated Parkinson's Disease
por: Morgan, John C., et al.
Publicado: (2014)

Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs
por: Mizuno, Yoshikuni, et al.
Publicado: (2017)

Starr–Edwards aortic valve: 50+ years and still going strong: a case report
por: Amrane, Mourad, et al.
Publicado: (2017)

The Kraepelinian dichotomy – going, going... but still not gone
por: Craddock, Nick, et al.
Publicado: (2010)

Neuropathy in Parkinson’s Disease Patients with Intestinal Levodopa Infusion versus Oral Drugs
por: Jugel, Constanze, et al.
Publicado: (2013)

Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson’s disease
por: Hong, Jin Yong, et al.
Publicado: (2020)

Modulation of Habit Formation by Levodopa in Parkinson's Disease
por: Marzinzik, Frank, et al.
Publicado: (2011)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
por: Haddad, Fatma, et al.
Publicado: (2017)

Successful Utilization of Levodopa in HIV-Induced Parkinsonism
por: Almajali, Mohammad, et al.
Publicado: (2020)

Mechanisms of peripheral levodopa resistance in Parkinson’s disease
por: Beckers, Milan, et al.
Publicado: (2022)

Determinants of Levodopa Responsiveness in Patients with Vascular Parkinsonism
por: Goyal, Sheetal, et al.
Publicado: (2022)

Comparison of Endothelial Progenitor Cells in Parkinson's Disease Patients Treated with Levodopa and Levodopa/COMT Inhibitor
por: Lee, Phil Hyu, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_sehnq2f8gu7e9l3rn9lbaq17bl